Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Key to Leveraging Emerging Approaches in Lung Cancer Lies in Balancing Benefit With Risk

May 28th 2021

Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.

Adjuvant Osimertinib Approved in Europe for Early-Stage EGFR+ NSCLC

May 28th 2021

The European Commission has approved osimertinib for the adjuvant treatment of adult patients with early-stage EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

Sugemalimab Shows Prolonged PFS in Stage III NSCLC

May 28th 2021

The investigational PD-L1 inhibitor sugemalimab prolonged progression-free survival in patients with locally advanced, unresectable stage III non–small cell lung cancer without disease progression after concurrent or sequential chemoradiation.

Real-World Data Reflect Shorter Survival With Pembrolizumab in Older NSCLC Population

May 28th 2021

Pembrolizumab alone and in combination with chemotherapy was associated with shorter overall survival compared with the data demonstrated in the registrational clinical trials in older Medicare patients with advanced non–small cell lung cancer, providing real-world insight into the prognosis of older patients with NSCLC who are treated with immunotherapy.

A Multidisciplinary Approach to Reflex Testing in NSCLC

May 27th 2021

Gary Doherty, MRCP, PhD, and Christian Grohé, MD, discuss the multidisciplinary approach to molecular testing for EGFR mutations in NSCLC and the importance of reflex testing to limit delays in receiving results.

Dr. Niu on Treatment Updates in RET+/KRAS+ NSCLC

May 27th 2021

Jason Niu, MD, PhD, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer.

Molecular Testing in Resectable NSCLC

May 27th 2021

Solange Peters, MD, PhD, reviews factors to consider for molecular testing in early stage non–small cell lung cancer and discusses the role of single-gene assays and next-generation sequencing panels.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

Dr. Bardoni on the Importance of the LIBRETTO-001 Trial With Selpercatinib in RET+ NSCLC

May 26th 2021

Rodolfo Bordoni, MD, discusses the importance of the phase 1/2 LIBRETTO-001 trial with selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

Neoadjuvant Nivolumab/Ipilimumab Enhances Pathologic Responses in Resectable NSCLC

May 26th 2021

The addition of neoadjuvant ipilimumab to nivolumab resulted in higher rates of major pathologic response and pathologic complete response, while enhancing tumor immune cell infiltrates in patients with resectable non–small cell lung cancer, according to data from the phase 2 NEOSTAR trial.

Targeted Therapies Continue to Make Strides in Oncogene-Driven NSCLC

May 25th 2021

Andrea Saltos, MD, provides perspective on the use of targeted therapy across EGFR-, RET-, and MET-positive NSCLC.

Dr. Strauss on Future Research Directions in SCLC

May 25th 2021

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Cemiplimab Granted Positive EU Opinion for Advanced NSCLC and Basal Cell Carcinoma

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab for use in 2 advanced cancers: non–small cell lung cancer and basal cell carcinoma.

Research Efforts Examining Novel Radiation Approaches Flourish at Fox Chase Cancer Center

May 21st 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

FDA Approves Amivantamab for EGFR Exon 20–Positive NSCLC

May 21st 2021

The FDA has approved amivantamab-vmjw as the first treatment for adult patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations.

Smoking Cessation Support Plays a Vital Role in Improving Lung Cancer Screening

May 21st 2021

Results of the National Lung Screening Trial demonstrated a 20% decrease in lung cancer mortality in individuals aged 55 to 74 years with a 30 pack-year smoking history using a low-dose computed tomography scan.

Lurbinectedin Adds Complexity to Second-line Treatment Selection in Extensive-Stage Small Cell Lung Cancer

May 20th 2021

Bruna Pellini, MD, discusses the current state of treatment in ES-SCLC, the importance of including a diverse and representative patient population in clinical trials, and ongoing research in ES-SCLC.

Research Prevails in NSCLC Despite the Challenges Wrought by COVID-19

May 20th 2021

Ullas Batra, MBBS, MD, DM, discusses the durability of targeted therapy in advanced NSCLC and the movement of targeted therapy and immunotherapy into earlier stages of disease.

SBRT Appears to Be Safe, Feasible in Oligometastatic Disease With Multiple Metastases

May 20th 2021

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Dr. Pellini on the Challenges of Using Topotecan as a Comparator Arm in Recurrent ES-SCLC

May 19th 2021

Bruna Pellini, MD, discusses the challenges of using topotecan as a comparator arm for second-line clinical trials in extensive-stage small cell lung cancer.